نتایج جستجو برای: everolimus

تعداد نتایج: 3889  

2016
Serafino Conforti Stefano Minardi Ludovica Conforti Salvatore Turano Stefania Bilotta Emmanuelle Vilardo Salvatore Palazzo

INTRODUCTION Stomatitis is a common and potentially dose-limiting adverse event of the mammalian target of rapamycin (mTOR) inhibitor therapy. To minimize dose reductions or treatment delays that may affect therapeutic outcomes, management includes patient education, pain management strategies, and drug treatment. The aim of this study was to evaluate the effectiveness of a topically-applied ga...

Journal: :The Journal of pharmacology and experimental therapeutics 2009
Roberta Baetta Agnese Granata Monica Canavesi Nicola Ferri Lorenzo Arnaboldi Stefano Bellosta Pascal Pfister Alberto Corsini

Monocytes/macrophages recruited into the arterial wall during atherogenesis are crucial in the initiation and progression of atherosclerosis and play a fundamental role in the destabilization process that is the main causal event of acute coronary syndromes. In the present study, we investigated the effect of the mammalian target of rapamycin inhibitor everolimus on macrophage accumulation with...

2017
Yu-Hua Chao Yin-Chen Chang Han-Ping Wu Ching-Tien Peng Te-Fu Weng Kang-Hsi Wu

Acute graft-versus-host disease (aGVHD) is a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Due to the poor prognosis for patients not responding to first-line steroids treatment, improvements in aGVHD therapy are needed. Everolimus is a promising candidate that combines immunosuppressive properties with anti-neoplastic effects. Her...

2014
D J A R Moes J J Swen J den Hartigh T van der Straaten J J Homan van der Heide J S Sanders F J Bemelman J W de Fijter H J Guchelaar

Cyclosporine, everolimus, and tacrolimus are the cornerstone of immunosuppressive therapy in renal transplantation. These drugs are characterized by narrow therapeutic windows, highly variable pharmacokinetics (PK), and metabolism by CYP3A enzymes. Recently, the decreased activity allele, CYP3A4*22, was described as a potential predictive marker for CYP3A4 activity. This study investigated the ...

2014
Rana Baraz Adam Cisterne Philip O. Saunders John Hewson Marilyn Thien Jocelyn Weiss Jordan Basnett Kenneth F. Bradstock Linda J. Bendall

Increasingly, anti-cancer medications are being reported to induce cell death mechanisms other than apoptosis. Activating alternate death mechanisms introduces the potential to kill cells that have defects in their apoptotic machinery, as is commonly observed in cancer cells, including in hematological malignancies. We, and others, have previously reported that the mTOR inhibitor everolimus has...

2015
Avital Nahmias Simona Grozinsky-Glasberg Asher Salmon David J Gross

UNLABELLED Approximately 35% of the pancreatic neuroendocrine tumors (pNETs) are functional, the most common of which is an insulinoma. Rarely can initially nonfunctioning tumor undergo biological transformation to a hormone-secreting tumor with subsequent changes in the clinical picture. We present here three unique patients with long-standing pNETs who developed life-threatening hyperinsuline...

Journal: :Blood 2015
Thomas E Witzig Craig Reeder Jing Jing Han Betsy LaPlant Mary Stenson Han W Tun William Macon Stephen M Ansell Thomas M Habermann David J Inwards Ivana N Micallef Patrick B Johnston Luis F Porrata Joseph P Colgan Svetomir Markovic Grzegorz S Nowakowski Mamta Gupta

Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in a phase 2 trial. The mTOR pathway was activated in all 6 TCL cell lines tested and everolimus strongly inhibited malignant T-cell proliferation wi...

Journal: :Lancet 2013
David Neal Franz Elena Belousova Steven Sparagana E Martina Bebin Michael Frost Rachel Kuperman Olaf Witt Michael H Kohrman J Robert Flamini Joyce Y Wu Paolo Curatolo Petrus J de Vries Vicky H Whittemore Elizabeth A Thiele James P Ford Gaurav Shah Helene Cauwel David Lebwohl Tarek Sahmoud Sergiusz Jozwiak

BACKGROUND Tuberous sclerosis complex is a genetic disorder leading to constitutive activation of mammalian target of rapamycin (mTOR) and growth of benign tumours in several organs. In the brain, growth of subependymal giant cell astrocytomas can cause life-threatening symptoms--eg, hydrocephalus, requiring surgery. In an open-label, phase 1/2 study, the mTOR inhibitor everolimus substantially...

Journal: :Anticancer Research 2021

Background: Osteosarcoma is the most frequent malignant bone neoplasm. The efficacy of combination therapy a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and mammalian-target-of-rapamycin (mTOR) was previously reported in several cancer types. In present study, we evaluated palbociclib (CDK inhibitor) everolimus (mTOR on an osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model....

2016
Caroline E. Nunes-Xavier Karine Flem Karlsen Christina Tekle Cathrine Pedersen Tove Øyjord Vesa Hongisto Jahn M. Nesland Ming Tan Kristine Kleivi Sahlberg Øystein Fodstad

B7 family proteins are important immune response regulators, and can mediate oncogenic signaling and cancer development. We have used human triple-negative breast cancer cell lines with different expression levels of B7-H3 to evaluate its effects on the sensitivity to 22 different anticancer compounds in a drug screen. API-2 (triciribidine) and everolimus (RAD-001), two inhibitors that target t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید